The Centers for Medicare and Medicaid Services said it will limit coverage of Biogen’s Aduhelm to people enrolled in clinical trials. “CMS is determining if the drug is considered reasonable and necessary, meaning that the benefits of improvement of cognition outweigh the harms in the Medicare population,” CMS chief medical officer Lee Fleisher said. (Politico)

Sanofi is spending $75 million upfront to license Korean biotech ABL Bio’s bispecific antibody, ABL301. The antibody is designed to penetrate the blood-brain barrier in the treatment of Parkinson’s disease. (Endpoints News)

The sentencing of former Theranos CEO Elizabeth Holmes will likely happen in September. Holmes was convicted of federal fraud charges, including three counts of wire fraud and one count of conspiracy to commit wire fraud, last week. (CNBC Weekly)

Catching “flurona,” or COVID-19 and the flu at the same time, is possible but uncommon, according to the Centers for Disease Control and Prevention. The CDC is monitoring cases of both infections among hospitalized people. (Business Insider)

Pfizer’s COVID-19 booster shot can be administered safely alongside its pneumonia vaccine, the company said Wednesday. New study results showed the two shots were safe and effective when administered together in people aged 65 and older. (Reuters)